BeOne Medicines Ltd. ONC
What the 10-K filed Feb 26, 2026 says off the balance sheet
10-K notesRisks that are not on the face of the balance sheet. Tickdelta picks sentences with specifics and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed Feb 27, 2025.
Big customers
Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).
New “For the year ended December 31, 2025, sales to the Company’s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5%, 17.5% and 10.1% of product revenue, respectively, and collectively, represented approximately 37.1% of trade accounts receivable as of December 31, 2025.”
18.5% in the 10-K filed 2026-02-26
Read it in the 10-K
“For the year ended December 31, 2024, sales to the Company’s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.0%, 16.9% and 11.1% of product revenue, respectively, and collectively, represented approximately 51.0% of trade accounts receivable as of December 31, 2024.”
18% in the 10-K filed 2026-02-26, 18% in the one filed 2025-02-27
Read it in the 10-K
Key suppliers
Parts or manufacturing that depend on one or a few suppliers.
“Third-party payors also are seeking to encourage the use of generic or biosimilar products or entering into sole source contracts with healthcare providers, which could effectively limit the coverage and level of reimbursement for our medicines and have an adverse impact on the market access or acceptance of our medicines.”
Read it in the 10-K
“Currently, the raw materials for our manufacturing activities are supplied by multiple source suppliers, although portions of our supply chain may rely on sole source suppliers.”
Read it in the 10-K
Lawsuits and legal claims
Pending cases, settlements and what the company has set aside for them.
“For a description of risks relating to these legal proceedings, see “Part I—Item 1A—Risk Factors” of this Annual Report, including the discussion under the headings entitled “Risks Related to Our Intellectual Property.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment.”
Read it in the 10-K
“Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.”
Read it in the 10-K
New “On February 25, 2026, our subsidiaries, BeOne Medicines USA Inc. and BeOne Medicines I GmbH, filed a patent infringement suit under the Hatch-Waxman Act against Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (collectively, “Zydus”) in the United States District Court for the District of New Jersey.”
Read it in the 10-K
Guarantees and indemnities
Promises to pay someone else's debts or losses if they cannot.
No specific sentence about this in the 10-K.
Debt covenants
Conditions in loan agreements that, if broken, can make debt due early.
New “In 2025 we generated proceeds from long-term debt of $855.0 million which was used to pay off all existing short-term working capital loans, and include certain restrictive covenants as laid out further below with respect to certain coverage ratios and maximum investment amounts.”
Read it in the 10-K
“Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of our loans in the event of default.”
Read it in the 10-K
“As of December 31, 2025, we are in compliance with all covenants of our material debt agreements.”
Read it in the 10-K
“Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default.”
Read it in the 10-K
“As of December 31, 2025, the Company was in compliance with all covenants of its material debt agreements.”
Read it in the 10-K
Commitments off the balance sheet
Contracts the company must pay for later: purchase obligations, take-or-pay deals.
New “As of December 31, 2025, purchase commitments amounted to $205.2 million, of which $24.9 million related to non-utilization fees and minimum purchase requirements for supply purchased from CMOs and $180.3 million related to binding purchase order obligations of inventory from Amgen.”
Read it in the 10-K
New “As of December 31, 2025, the Company had purchase commitments amounting to $205,175, of which $24,921 related to non-utilization fees and minimum purchase requirements for supply purchased from contract manufacturing organizations and $180,254 related to binding purchase order obligations of inventory from Amgen.”
Read it in the 10-K
Companies it names
Tracked companies that its latest 10-K or its 8-Ks of the last year call a customer or a supplier.
No other tracked company is named as a customer or a supplier in the latest filings.
Companies that name it
Tracked companies whose latest 10-K or 8-Ks call it a customer or a supplier.
No other tracked company names it as a customer or a supplier in the latest filings.
Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K
Sources
The notes to the financial statements, Legal Proceedings and the MD&A of the latest 10-K (and, for customers and suppliers, Business and Risk Factors), quoted as filed.
Also
Debt: the debt note in numbers.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.